Critical therapeutics is awarded U.S. patents for methods to diagnose and treat inflammatory disease

December 02, 2002

Cambridge, Massachusetts, December 2, 2002 -- Critical Therapeutics, Inc. (CTI) today announced that it has been awarded three U.S. patents covering methods to diagnose, predict the severity of and treat serious inflammatory diseases including sepsis, a bloodstream infection that is the nation's tenth leading cause of death.

The patents, which were issued by the United States Patent and Trademark Office, relate to a protein within the High Mobility Group (HMGB) family of nuclear proteins. This protein, HMGB1, has been identified as an important mediator of the body's inflammatory response to infection, ischemia and injury. Increased levels of HMGB1 have been implicated in sepsis and other major inflammatory diseases including rheumatoid arthritis.

"Therapies targeting HMGB1 can potentially afford significant benefits to critically ill patients stricken with serious systemic inflammatory disease," said Walter Newman, Ph.D., CTI's chief scientific officer. "As a result, these patents give CTI a strong intellectual property foothold as we move forward with discovery and development initiatives related to this protein."

U.S. patent number 6,468,533 B1, "Antagonists of HMGB1 for Treating Inflammatory Conditions," provides a pharmaceutical composition comprised of an antibody that binds HMGB1. The antibody, in turn, is believed to dramatically reduce the "cytokine cascade," or overproduction, of HMGB1 that triggers sepsis and other inflammatory diseases.

U.S. patent number 6,448,223 B1, "Antagonists of HMGB1 for Treating Inflammatory Conditions," covers a method of administering antibodies to treat the inflammatory illness. These antibodies neutralize the pro-inflammatory effect of HMGB1.

U.S. patent number 6,303,321 B1, "Methods of Diagnosing Sepsis," provides for a method to diagnose the disease and to predict its severity by measuring the concentration of HMGB1 in the serum.

The Society of Critical Care Medicine defines sepsis as an overwhelming infection that causes heart, blood vessel and cell dysfunction. High levels of HMGB1 have been found in the serum of patients with critical illness and sepsis. (Wang et al., 1999; Ombrellino et al, 1999) and in the synovial fluid of patients with rheumatoid arthritis (Kokkola et al., 2002). In animal models, neutralization of the protein has been associated with improvement in collagen-induced arthritis and increased survival in endotoxemia and sepsis, even when treatment begins after the onset of disease.

According to the Society of Critical Care Medicine, severe sepsis strikes approximately 750,000 people in the U.S. annually. The disease, which is expected to cause 215,000 deaths in the U.S. this year, is the leading cause of death in the non-coronary intensive care unit.
About Critical Therapeutics
Critical Therapeutics, based in Cambridge, Massachusetts, is a privately held biotechnology company focused on critical care medicine. CTI's mission is the discovery and clinical development of novel therapies for the treatment of acute trauma, cardiopulmonary disease and infectious and inflammatory illness.

Glossary of terms*

Cytokine cascade (systemic inflammatory response syndrome): A progressive state of systemic inflammation characterized by a white blood cell count greater than 12,000/mm3 or less than 4000/mm3, temperature greater than 38°C or < 36°C, tachycardia, tachypnea, and decreased blood carbon dioxide levels.

Endotoxemia: A systemic inflammatory response to infection, in which there is fever or hypothermia, tachycardia, tachypnea, and evidence of inadequate blood flow to internal organs.

Ischemia: A temporary deficiency of blood flow to an organ or tissue. The deficiency may be caused by diminished blood flow either through a regional artery or throughout the circulation.

Sepsis: A systemic inflammatory response to infection, in which there is fever or hypothermia, tachycardia, tachypnea, and evidence of inadequate blood flow to internal organs.

Serum: The watery portion of the blood after coagulation

*[Taber's Cyclopedic Medical Dictionary]

Sharon Merrill Associates, Inc.

Related Rheumatoid Arthritis Articles from Brightsurf:

Reducing dementia in patients with rheumatoid arthritis
The incidence of dementia in patients with rheumatoid arthritis is lower in patients receiving biologic or targeted synthetic disease modifying antirheumatic drugs (DMARDs) than in patients who receive conventional synthetic DMARDs, according to a new study.

Is rheumatoid arthritis two different diseases?
While disease activity improves over time for most rheumatoid arthritis (RA) patients, long-term outcomes only improve in RA patients with autoantibodies, according to a new study published this week in PLOS Medicine by Xanthe Matthijssen of Leiden University Medical Center, Netherlands, and colleagues.

Does the Mediterranean diet protect against rheumatoid arthritis?
Previous research has demonstrated a variety of health benefits associated with the Mediterranean diet, which is rich in olive oil, cereals, fruit and vegetables, fish, and a moderate amount of dairy, meat, and wine.

Reducing corticosteroid use in rheumatoid arthritis
Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects?

Rheumatoid arthritis patients under treatment with methotrexate
Patients with rheumatoid arthritis (RA) often suffer from what is referred to as interstitial lung disease (ILD).

Rheumatoid arthritis -- can its onset be delayed or prevented?
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that leads to significant health issues as well as high treatment costs.

Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.

Prospect of a new treatment for rheumatoid arthritis
An international research group led by Charité -- Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

Can rare lymphocytes combat rheumatoid arthritis?
Immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg have demonstrated that ILC2, a group of rare lymphoid cells, play a key role in the development of inflammatory arthritis.

Rheumatoid arthritis meets precision medicine
Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients, reports a new multi-site study.

Read More: Rheumatoid Arthritis News and Rheumatoid Arthritis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to